India

Medical Technologies Sector Review

Definition and scale of sector

Why the sector was chosen in the West Midlands

Top of page

OPPI Position Paper on Medical Diagnostics and Medical Devices - September 2011

The OPPI Medical Diagnostics and Devices Committee represents a consortium of research based Indian and multinational organizations committed towards development of Medical Technology Industry in India. Healthcare is one of the fastest growing industries in India and is valued at approximately US$ 60 billion. It is poised to have a strong growth in the coming years.The Indian healthcare sector is expected to reach US$ 275 billion by 2020. (Source: Fitch Ratings Agency) The expected growth is based on the facts such as: India has a huge young population that is ageing; its economic growth is high; the lifestyle and hence the related disease pattern prevalence is changing from communicable to non-communicable diseases With healthcare becoming ever more complex, technology is providing answers to some of the most challenging aspects of medicine. Technological maturity coupled with constant innovation in electronics and software is transforming the healthcare industry to meet these challenges.

In fact, the healthcare scenario in India is witnessing a rapid transformation. One end of spectrum, we have best in class tertiary care hospitals and on the other end people even lack access to primary healthcare. There is a near absence of accessible and affordable quality healthcare for a large part of its population This gap is either due to non-availability of facilities or their non-affaordability. Accessibility remains one of the key concerns and contributing reasons include rural urban divide that exists in India – 72% of the population resides in the rural sector whereas majority of the healthcare setup is located in the urban cities. Over 70% of Indians pay out of pocket for all healthcare related expenses. Also, healthcare is delivered both through the public and the private sector. Currently, the private sector predominates; with 80% of the healthcare expenditures coming from private sector only. The Central Government spend on healthcare is just about 1% of its overall budgets.

Source: Organisation Of Pharmaceutical Producers of India (OPPI)

FOR THE FULL REPORT PLEASE CLICK HERE

Enhancing access to healthcare through innovation Medical technology in India - June 2011

India is a signatory to the Millennium Development Goals (MDGs). These goals, agreed to by a community of nations and international organisations in 1992 represent the most comprehensive and specific development goals ever agreed upon by the world. MDGs represent the will of the world’s nations to achieve development objectives by the year 2015. The importance of healthcare in the MDGs is highlighted by the fact that three out of eight goals, six out of 21 targets and 18 out of 60 indicators pertain to healthcare. India is also a signatory to the Alma Ata Declaration which promised Health for All by the year 2000.

Medical technology plays a vital role in delivery of healthcare services in India. Medical professionals rely on medical technology for tests and investigations to aid their clinical decision making. Medical technology also plays a critical role in the treatment of patients and their return to normal life. Innovation in medical technology can therefore be crucial for the Indian healthcare system to improve access, enhance quality and reduce costs.

Medical technology is a nascent sector in India and the opportunities for innovation-led growth are immense. The sector however does face significant challenges. The size and structure of the sector in India, the growth projections, the need for innovation, the five pillars which facilitate innovation, the challenges to innovation and the critical role the government needs to play in ensuring sustainable growth are the areas that will be addressed in this report.

Source: Federation of Indian Chamber of Commerce and Industry (FICCI)

FOR THE FULL REPORT PLEASE CLICK HERE

Biotechnology and Pharmaceutical Opportunities in India - December 2010

India is a priority emerging market for UK Trade & Investment. Recent developments in the life sciences sector in India indicate increasing business opportunities for the UK’s Biotechnology & Pharmaceutical sector.
The Indian biotech sector is in a unique crossroads. On one hand it is forced to meet the internal and more public-centered healthcare objectives of reaching out the right medication or treatment to the needy and on the other hand it is forced to remain competitive in the international markets.
Following the phenomenal success of its information technology industry, India is fast emerging as an important player in the biotechnology sector in the Asia–Pacific Region. The large pool of scientific talent available at a reasonable cost, a wealth of R & D institutions, a rich and varied bio-diversity, a flourishing pharmaceutical industry, strong IT skills and an English speaking population have all placed India favourably in the global market. Biotechnology is the new sunrise sector in India and is poised to take the country into the next big league of internal and international investment. The country has traditionally done well in pharmaceuticals sector and this has helped evolve the biotech sector over the last 10 years. A few years ago India had only 30 biotech companies worth talking about. Today about 380 companies are active in the modern biotechnology segment with combined revenues of about $4 billion. This revenue is expected to reach the $5 billion mark by 2010.

Source: UK Trade and Investment (UKTI) 

FOR THE FULL REPORT PLEASE CLICK HERE

Healthcare Sector Report - December 2010

The Indian healthcare sector is expected to become a US$ 280 billion industry by 2020 with spending on health estimated to grow 14 per cent annually, according to a report by an industry body. "Healthcare has emerged as one of the most progressive and largest service sectors in India with an expected GDP spend of 8 per cent by 2012 from 5.5 per cent in 2009. It is believed to be the next big thing after IT and predicted to become a US$ 280 billion industry by 2020," the report said.
At present the sector is estimated to be around US$ 40 billion and will grow to US$ 78.6 billion by 2012.
As per a study by an industry body and Ernst & Young, India would require another 1.75 million beds by the end of 2025. The public sector however is likely to contribute only around 15-20 per cent of the required US$ 86 billion investment. The corporate India is therefore, leveraging on this business potential and various health care brands have started aggressive expansion in the country. Some of the companies that plan to increase their footprints include Anil Ambani’s Reliance Health, the Hindujas, Sahara Group, Emami, Apollo Tyres and the Panacea Group.
Sahara Group is planning several healthcare projects such as a 200-bed multi-specialty tertiary care hospital at Gorakhpur in Uttar Pradesh, a 1,500-bed multi super-specialty, tertiary care hospital at Aamby Valley City and 30-bed multi-speciality secondary care hospitals across all the 217 Sahara City Homes Townships.

Source: India Brand Equity Foundation (IBEF)

FOR THE FULL REPORT PLEASE CLICK HERE

Pharmaceuticals Sector Report - December 2010

India's pharmaceutical industry is now the third largest in the world in terms of volume and stands 14th in terms of value. According to data published by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, the total turnover of India's pharmaceuticals industry between September 2008 and September 2009 was US$ 21.04 billion. Of this the domestic market was worth US$ 12.26 billion.
The Indian pharmaceuticals market is expected to reach US$ 55 billion in 2020 from US$ 12.6 billion in 2009, according to a report ‘India Pharma 2020: Propelling access and acceptance, realising true potential’ by McKinsey & Company. The report states that the market has the further potential to reach US$ 70 billion by 2020 in an aggressive growth scenario.
Moreover, according to an Ernst & Young and industry body study, the increasing population of the higher-income group in the country, will open a potential US$ 8 billion market for multinational companies selling costly drugs by 2015. Besides, the report said the domestic pharma market is estimated to touch US$ 20 billion by 2015, making India a lucrative destination for clinical trials for global giants.

Source: India Brand Equity Foundation (IBEF)

FOR THE FULL REPORT PLEASE CLICK HERE

Biotechnology Sector Report - November 2010

The Indian biotechnology sector is one of the fastest growing knowledge-based sectors in India and is expected to play a key role in shaping India's rapidly developing economy. With numerous comparative advantages in terms of research and development (R&D) facilities, knowledge, skills, and cost effectiveness, the biotechnology industry in India has immense potential to emerge as a global key player.
The Indian biotech industry grew threefold in just five years to report revenues of US$ 3 billion in 2009-10, a rise of 17 per cent over the previous year, according to the eighth annual survey conducted by the Association of Biotechnology-Led Enterprises (ABLE) and a monthly journal, BioSpectrum, based on inputs from over 150 biotech companies.
The biopharma sector contributed nearly three-fifth to the industry's revenues at US$ 1.9 billion, a rise of 12 per cent, followed by bioservices at US$ 573 million and bioagri at US$ 420.4 million. The remaining revenue came from the bioindustrials US$ 122.5 million and bioinformatics US$ 50.2 million segments.

Source: India Brand Equity Foundation (IBEF)

FOR THE FULL REPORT PLEASE CLICK HERE

Healthcare Opportunities in India - May 2010

The Indian healthcare industry is estimated togrow from the current level of around Rs 1500 billion (US$ 37.5 billion) to over Rs 3000 billion (US$ 75 billion) by 2012. At Rs 690 billion (£10 billion), private spending accounts for asignificant chunk of the healthcare deliverymarket. The healthcare sector in India iswitnessing large private sector investments innew facilities spurred by a wide demand-supply gap in healthcare delivery. Government isencouraging private participation due toconstraints in public funding capability. Importincidence is high - almost 70%-80% of medical equipment for private hospitals is imported.Peak import duties have been lowered to bring India in line with WTO norms.
India is now emerging as a healthcare hub in Asia due to the growing number of multi and single superspeciality tertiary care hospitals. Customer expectations for quality healthcare from private hospitals is high and most urban hospitals are striving to provide state-of-the-art care in almost all healthcare specialities. The intention of these leading private hospitals is to provide world-class international quality healthcare service at affordable rates. As a consequence, medical tourism (or medical value travel) is a high interest area for these hospitals. The rapid expansion in the sector by way of several greenfield and expansion projects in hospitals and medical colleges across India provides immediate opportunities for UK healthcare technology, equipment and service providers and consultants.

Source: UK Trade and Investment (UKTI) 

FOR THE FULL REPORT PLEASE CLICK HERE

Biotechnology & Pharmaceuticals Sector Report - December 2008

India is a priority high growth market for UK Trade & Investment.  Recent developments in the sector in India indicate increasing business opportunities for the UK's biotechnology sector.
Following the phenomenal success of its information technology industry, India is fast emerging as an important player in the biotechnology sector in the Asia-Pacific Region.  The large pool of scientific talent available at a reasonable cost, a wealth of R & D Institutions, a rich and varied bio-diversity, a flourishing pharmaceutical industry, strong IT skills and an English speaking population has placed India favourably in the global market.
A few years ago India had only 30 biotech companies worth talking about. Today about 325 companies are active in the modern biotechnology segment with combined revenues of about $2 billion. (Source: Biospectrum-Able Biotech Survey, 2008). It is expected to reach the target of $5 billion by 2010. The Indian biotech industry reported revenues of $ 2.5 billion in the just concluded FY 2007-08, reveals the 6th BioSpectrum-ABLE Biotech Industry Survey. The heady growth achieved by the industry in the last five years dropped to 20% in 2007-08 due to appreciation of the rupee and price pressures in global markets.

Source: UK Trade and Investment (UKTI) 

FOR THE FULL REPORT PLEASE CLICK HERE

Healthcare and Medical Sector Report - November 2008

According to Technopak India Healthcare Trends 2008, the Indian healthcare industry is estimated to grow from current Rs 1500 billion (US$ 37.5 billion) to over Rs 3000 billion (US$ 75 billion) by 2012. At Rs 690 billion (£8 billion), private spending accounts for a significant chunk of the healthcare delivery market. The healthcare sector in India is witnessing large private sector investments in new facilities spurred by a wide demand-supply gap in healthcare delivery. Government is encouraging private participation due to constraints in public funding capability. Import incidence is high - almost 70%-80% of medical equipment for hospitals is imported. Peak import duties have been lowered to bring India in line with WTO norms.
India is now emerging as a healthcare hub in Asia due to the growing number of multi and single superspeciality tertiary care hospitals. Customer expectations for quality healthcare from private hospitals is high and most urban hospitals are striving to provide state-of-the-art care in almost all healthcare specialities. The intention of these leading private hospitals is to provide world-class international quality healthcare service at affordable rates. As a consequence, medical tourism, is a high interest area for these hospitals.

Source: UK Trade and Investment (UKTI)

FOR THE FULL REPORT PLEASE CLICK HERE

Pharmaceuticals- Market and Opportunities - A Sector Report From IBEF - July 2008

India is among the fastest growing pharmaceutical markets in the workld.  The domestic pharmaceutical market recorded sales of US$ 7.3 billion in 2006 with a growth of 17.5 per cent over the previous year. Of this, retail sales were US$ 6.2 billion, while institutional sales were estimated to be around US$ 1.2 billion

Source: India Brand Equity Foundation (IBEF)

FOR FULL REPORT PLEASE CLICK HERE

 

Pharmaceuticals Sector Report from IBEF - April 2008

The Indian pharmaceutical sector is witnessing tremendous growth with the contract research and clinical trials businesses taking wing, and the new patent regime opening new avenues for players in the country. The country's pharmaceutical market is a US$ 7.3 billion opportunity with the domestic retail market expected to cross the US$ 10 billion mark in 2010 and be worth an estimated US$ 12-13 billion in 2012.

Source: India Brand Equity Foundation (IBEF)

FOR THE FULL REPORT PLEASE CLICK HERE

Healthcare Sector Report from IBEF - April 2008

India's healthcare sector has been growing rapidly and estimated to be worth US$ 40 billion by 2012, according to Pricewaterhouse Coopers in its report, 'Healthcare in India: Emerging market report 2007'. Revenues from the healthcare sector account for 5.2 per cent of the GDP, making it the third largest growth segment in India.

The sector's growth will be driven by the country's growing middle class, which can afford quality healthcare. Over 150 million Indians have annual incomes of more than US$ 1,000, and many who work in the business services sector earn as much as US$ 20,000 a year. Today at least 50 million Indians can afford to buy Western medicines-a market only 20 per cent smaller than that of the UK.

Source: India Brand Equity Foundation (IBEF)

FOR THE FULL REPORT PLEASE CLICK HERE

Biotechnology Sector Report from IBEF - April 2008

The Indian biotech industry - accounting for 2 per cent of the global biotech market - has the potential to develop as a key player, generating revenues worth US$ 5 billion. The domestic biotechnology industry is now a US$ 3 billion sector, registering 30 per cent growth in 2007-08 over the previous year. Furthermore, it is estimated that this sector will grow to occupy 140 million square feet by 2010, creating employment for a million by means of its products as well as its services. Significantly, an Ernst and Young survey recognises India as one of the emerging biotech leaders, ranked third in the Asia-Pacific region based on the number of biotech companies in the country.

Source: India Brand Equity Foundation (IBEF)

FOR THE FULL REPORT PLEASE CLICK HERE

Discovering new drugs - A Report from IBEF - December 2007

In the late 1990s when the life threatening Hepatitis B took an epidemic form all over India, a little known company from Hyderabad teamed up with a host of leading hospitals across the nation to develop a drug, which is today popularly known as Shanvac-B.

It happens to be the fi rst indigenously developed Hepatitis B vaccine in India, heralding the arrival of innovation in the pharmaceutical and biotechnology industry.

Source: India Brand Equity Foundation (IBEF)

FOR THE FULL REPORT PLEASE CLICK HERE

Biotech Boom - Gathering steam - A Report from IBEF - December 2007

India, which has earned a name worldwide as the most preferred destination for global Information Technology (IT) outsourcing and software services firms, is gradually making a mark in another high-tech sector - biotechnology. This sunrise sector, which has seen the entry of many new players both Indian and international, is poised to take the country to the big league with investments
flowing in from all corners. The country has traditionally done well in the pharmaceutical and drug industry. As an offshoot of the pharmaceutical industry, the biotechnology sector took shape over the last 10 years with many entrepreneurs making substantial investments in it.

According to Dr M.K. Bhan, Secretary, Department of Biotechnology, Government
of India, the industry - currently expanding at 37 per cent per annum - is growing phenomenally, and this can easily be sustained. It is projected to burgeon into a $5 billion sector by 2010.

Source: India Brand Equity Foundation (IBEF)

FOR THE FULL REPORT PLEASE CLICK HERE 

Biotechnology Sector Report - July 2007

India is a priority emerging market for UK Trade & Investment.  Recent developments in the sector in India indicate increasing business opportunities for the UK's biotechnology sector.

Following the phenomenal success of its information technology industry, India is fast emerging as an important player in the biotechnology sector in the Asia-Pacific Region.  The large pool of scientific talent available at a reasonable cost, a wealth of R & D Institutions, a rich and varied bio-diversity, a flourishing pharmaceutical industry, strong IT skills and an English speaking population has placed India favourably in the global market.

FOR THE FULL REPORT PLEASE CLICK HERE

Source: UK Trade and Investment  

Top of page            

Pharmaceutical Sector Review - July 2007

Biotechnology & Pharmaceuticals are a priority sector. From 01/01/2005, a new TRIPS-compliant IPR regime as mandated by the WTO is in place. Following the approval of the Patents (3rd Amendment) Bill by the Indian Parliament on 23 March 2005, the Indian Pharmaceuticals sector now merits an active watching brief.

The Indian Pharmaceutical sector is highly fragmented with over 20,000 registered units. The leading 250 pharmaceutical companies control 70% of the market, with the market leader Glaxo SKB having only a 5.4 % market share (CY 2004). The top 10 companies cover around 31% of the pharma market. Because of Government price controls and the fragmented nature of the market, it is an extremely competitive industry which has evolved around the opportunities presented in the regulated environment

FOR THE FULL REPORT PLEASE CLICK HERE  

Pharmaceutical - Overview from IBEF - July 2007

In 2007, the Indian pharmaceutical industry looks ahead at a colourful horizon, what with contract research and clinical trials businesses taking wing, and the new patent regime opening new avenues for players in the country.
Globally the Indian pharmaceutical industry ranks 4th in terms of volume (with an 8 per cent share in global sales) and 13th in terms of value (with a share of 1 per cent in global sales). Today, the sector today is in the front rank of India's science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology. A highly organised sector, the Indian pharmaceutical industry is estimated to be worth US$ 4.5 billion, growing at over 9 per cent annually.

FOR THE FULL REPORT PLEASE CLICK HERE

Source: India Brand Equity Foundation (IBEF)

Research and Development - Overview from IBEF - July 2007 

India is fast emerging as the global research and development (R&D) hub of the world. In the past ten years the country has moved from a peripheral position in knowledge and technology sectors to being at the core of the continuous flow of people, ideas and technologies around the world. In 2006 alone, for example, 100 of the world's top R&D companies employed more than 15,000 scientists in India.

FOR THE FULL REPORT PLEASE CLICK HERE

Source: India Brand Equity Foundation (IBEF)

Top of page

Science and Technology - Overview from IBEF - July 2007

India is fast emerging as the global research and development (R&D) hub of the world. In the past ten years the country has moved from a peripheral position in knowledge and technology sectors to being at the core of the continuous flow of people, ideas and technologies around the world. In 2006 alone, for example, 100 of the world's top R&D companies employed more than 15,000 scientists in India.

FOR THE FULL REPORT PLEASE CLICK HERE

Source: India Brand Equity Foundation (IBEF)

Top of page